Written in Blood
two patients died from infections arising from non-
engraftment and one died from GVHD. Another
patient died from severe GVHD at 13.9 months,
leading to a two-year survival rate of 84.6 percent.
Twenty-three patients (88%) experienced
engraftment. In the remaining three patients,
engraftment failed because of:
• death at day 71 (n=1)
• death at day 92 following a second
haploidentical hematopoietic cell
transplantation (HCT; n=1)
• survival at 31 months following a second
haploidentical HCT (n=1)
Almost half of patients (n=10; 45.8%) experi-
enced grade 2-4 acute GVHD; nine patients
(36%) developed chronic GVHD.
Overall, 18 of the 22 patients alive at last
follow-up had stopped active immunosuppression
“Unfortunately, not all patients
with SAA have eligible
cord blood units available,
justifying new prospective
clinical trials.”
—RÉGIS PEFFAULT DE LATOUR, MD, PhD